Document:

EX-10.1

 Exhibit 10.1 
 TRANSITION SERVICES AGREEMENT 
 This Transition Services Agreement
(this “Agreement”) is made by and between Peter A. Zorn (“Zorn”) and Targacept, Inc. (“Targacept” or the “Company”), including all Targacept predecessor entities and all
affiliated entities, and provides as follows. 
 RECITALS 

A. Zorn is presently employed by Targacept pursuant to an Employment Agreement dated March 13, 2008 (the “Employment
Agreement”), most recently serving as Targacept’s Senior Vice President, Legal Affairs, General Counsel and Secretary. 
 B. Zorn has decided to resign voluntarily and terminate his employment with the Company. 
 C. The Company and Zorn have agreed that it is in their mutual best interest to work cooperatively to ensure an appropriate and orderly transition following Zorn’s resignation. 

D. Targacept desires to engage Zorn as an independent contractor to provide the Company with access to his knowledge, experience with the
Company and certain services following his resignation, and Zorn desires to accept such engagement and provide the Company with access to such knowledge, experience and services, in each case on the terms and conditions set forth herein. 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Targacept and Zorn
hereby covenant and agree as follows: 
 1. RESIGNATION AND TERMINATION
OF EMPLOYMENT. Zorn acknowledges that, on August 13, 2013, he voluntarily tendered his resignation of employment and all offices held with the Company incident to his employment, effective at
the close of business on September 30, 2013 (the “Resignation Date”) and Targacept has accepted Zorn’s resignation effective on the Resignation Date. Zorn’s employment with the Company shall terminate on the
Resignation Date. 
 2. EFFECTIVENESS OF AGREEMENT. To
accept the terms of this Agreement, Zorn must return a signed copy of this Agreement to Targacept, Inc., 100 North Main Street, Suite 1510, Winston-Salem, NC 27101-4072, Attn: Stephen A. Hill, President and Chief Executive Officer and Attn: General
Counsel. This Agreement shall become effective on the eighth (8th) day after the date Zorn signs and returns a copy to the Company, but only if Zorn has not exercised the ADEA Revocation Right as defined in and as provided in Section 18.
For clarity, if Zorn exercises the ADEA Revocation Right, this Agreement shall be null and void and of no force or effect. 

3. ENGAGEMENT FOR TRANSITION PERIOD; TRANSITION
SERVICES. 
 (a) The Company hereby engages Zorn as an independent contractor for the
period beginning on the day following the Resignation Date, and, subject to Section 7, ending on December 31, 2013 (the “Transition Period”) to render, as an independent contractor, the Transition Services (as defined in
Section 3(b)), and Zorn hereby accepts such engagement, in each case subject to the terms and conditions of this Agreement. 

  
 Page 1 of 8

 (b) During the Transition Period, Zorn shall make himself available to Targacept to discuss
matters related to Targacept’s business, legal and regulatory affairs or otherwise to facilitate an orderly transition for the Company as the Company may reasonably request from time to time (the “Transition Services”);
provided that in no event shall (i) Zorn be required to provide more than five (5) hours of Transition Services in any week during the Transition Period, (ii) Zorn be required to travel to perform Transition Services and
(iii) the Company request that Zorn provide any legal advice or legal opinions during the Transition Period, whether as part of Transition Services or otherwise. The Company acknowledges and agrees that any and all information and service
provided by Zorn to the Company during the Transition Period, including all Transition Services, are provided solely for informational purposes and are not offered as and do not constitute legal advice or legal opinions. All requests for Transition
Services by Targacept shall be made or confirmed in writing or email by the Company’s highest ranking legal counsel or by the President and CEO before any such services are undertaken or provided. 

4. TRANSITION PAY AND BENEFITS. In consideration
and exchange for all of Zorn’s promises under this Agreement, the release and waiver set forth in Section 11 and Zorn’s performance of Transition Services in accordance with this Agreement, the Company shall provide Zorn with the
transition pay and benefits set forth below. 
 (a) The Company shall pay Zorn at a rate of $300 per hour
for his performance of any and all Transition Services under this Agreement. Zorn shall keep accurate records of his time spent on Transition Services each day, which shall be made available to Targacept upon request. Following the end of each month
during the Transition Period, Zorn shall submit an invoice to Targacept that includes the total hours spent by Zorn on the Transition Services for that month, rounded up to the nearest quarter hour, and a brief description of the services provided.
Such monthly invoices should be submitted to Targacept no later the 15th day of each month (or next business day thereafter). Such invoices shall be paid by Targacept within thirty (30) days. 
 (b) Subject to the terms and conditions of that certain letter agreement between Zorn and Targacept of even date herewith (the “Stock Option Letter Agreement”), the vesting of certain
Targacept stock options previously issued to Zorn will be accelerated and the exercise period of certain Targacept stock options previously issued to Zorn will be extended. The terms and conditions of the Stock Option Letter Agreement are hereby
incorporated by reference into this Agreement. 
 (c) The Company shall not be responsible for withholding taxes with respect to
payments and benefits provided to Zorn under this Agreement. Zorn shall be responsible for all federal, state and local tax liabilities arising from such payments and benefits, and Zorn agrees to indemnify and hold harmless the Company from any and
all tax liabilities arising from any and all payments and benefits provided under this Agreement. 
 5.
REIMBURSEMENT OF EXPENSES. To the extent that (i) the Company requests Zorn to travel, and Zorn agrees to travel, to perform Transition Services and (ii) the projected
expenses for such travel are approved prior to Zorn’s incurrence by the Company in such format or following such process as the Company may reasonably determine, the Company will reimburse Zorn for his reasonable airfare, lodging and meal
expenses actually incurred, subject to receipt by the Company of adequate supporting documentation and provided that the Company shall not be required to reimburse an amount greater than the amount of pre-approved projected expenses. Except as
provided in this Section 5, Zorn shall be responsible for all office, administrative, telephone (including cell phones, smart phones, PDAs, etc.), overhead and other expenses incurred in the performance of Transition Services or otherwise to
fulfill his obligations hereunder. 

  
 Page 2 of 8

 6. MANNER OF
PERFORMANCE. Zorn shall retain the right to control the time, manner and method of executing Transition Services, subject to the reasonable satisfaction of the Company and provided that, in any event, Zorn shall
comply with all applicable Company policies and procedures and all applicable laws, regulations and rules of any local, state, or federal unit of government. Zorn shall determine his daily work schedule and shall determine and work the number of
hours necessary to perform Transition Services in a timely, efficient and professional manner. Subject to Section 5, Zorn shall supply his own equipment and supplies needed to perform Transition Services. 

7. EARLY TERMINATION OF TRANSITION
PERIOD. Notwithstanding anything in this Agreement to the contrary, the Company may terminate the Transition Period effective immediately by written notice to Zorn in the event that: (a) Zorn breaches any
material term of this Agreement and, if curable, such breach has not been cured ten (10) days after the Company gives written notice of the breach to Zorn; or (b) the Company reasonably believes that Zorn (i) has engaged in theft,
fraud, embezzlement or unauthorized use of the property of the Company; or (ii) is convicted of a felony or engages in any other conduct that, in the reasonable judgment of the Company, causes damage to the Company’s reputation or standing
in the community or industry in which it operates; provided that, for clarity but without limiting the generality of the foregoing, a failure by Zorn in any month during the Transition Period to perform Transition Services reasonably requested by
Targacept shall constitute a material breach of this Agreement. Upon termination of the Transition Period, the Company’s obligations to provide compensation under Section 4(a) of this Agreement shall cease immediately and Zorn, for himself
and for his heirs, successors, assigns, or anyone else claiming under or through Zorn, agrees that neither he nor any of the foregoing shall have any right to further compensation under Section 4(a) of this Agreement beyond any compensation due
for any Transition Services actually provided by Zorn as of the effective date of such termination. 
 8.
INDEPENDENT CONTRACTOR STATUS; NO RIGHT TO BENEFITS. Zorn understands and agrees that the relationship created by this
Agreement is purely contractual and that no employment relationship is intended, or should be inferred, from this Agreement or from the performance of the Company’s obligations under this Agreement. Zorn’s relationship to the Company
during the Transition Period shall be that of an independent contractor, and Zorn shall not be entitled to, or eligible for, on either a prospective or a retrospective basis, any employee benefits under any plans or programs established or
maintained by the Company. 
 9. NO AUTHORITY TO
BIND. Zorn shall have no right or authority, expressed or implied, to commit or otherwise obligate the Company to any third party in any manner. Zorn agrees that the Company shall not be obligated to third
parties with which Zorn may make agreements or to which Zorn may direct payments without the Company’s prior written consent. 
 10. NO PRIOR OBLIGATION. Zorn acknowledges and agrees that: (a) the payments and benefits that Zorn receives or for which
Zorn is eligible under this Agreement are of value to Zorn; (b) the Company had no prior legal obligation to provide some or all of such payments and benefits; and (c) Zorn would not be entitled to some or all of such payments and benefits
if not for this Agreement. 

  
 Page 3 of 8

 11. GENERAL RELEASE AND
WAIVER OF CLAIMS BY ZORN. Zorn, for himself and for his heirs, successors, assigns, or anyone else claiming under or through Zorn, hereby forever
discharges and releases Targacept, its predecessor, affiliated or subsidiary entities, and its and their respective directors, officers, stockholders, affiliates, employees, agents, representatives, and assigns (all of the foregoing, collectively,
the “Releasees”), and each of them, from any and all claims, liabilities, actions or causes of action of any kind or character whatsoever, whether at law or in equity, whether known or unknown, whether contingent or absolute. This
general release and waiver of claims includes, without limitation, claims for personal injuries, back pay, losses or damage to real or personal property, economic loss or damage of any kind, breach of contract (express or implied), defamation,
breach of any covenant of good faith (express or implied), tortious interference with contract, wrongful termination, business or personal tort, misrepresentation, or any other losses or expenses of any kind (whether arising in tort, contract or by
statute) arising out of Zorn’s employment relationship with Targacept and any other alleged acts or omissions by the Releasees not expressly excluded herein. Zorn acknowledges that this general release and waiver of claims applies both to known
and unknown claims that may exist between Zorn and any of the Releasees as of the date he signs this Agreement. 
 Zorn
expressly acknowledges and agrees that this release and waiver of claims includes but is not limited to a release of any and all rights, claims, or causes of action arising under any employment, stock option or other agreement (whether written, oral
or implied) or under any state or federal constitution, statute, law, rule, regulation, or common-law principle of tort, contract or equity, except for the obligations of Targacept under this Agreement. This waiver of claims specifically includes
but is not limited to any action under the Age Discrimination in Employment Act of 1967, 29 U.S.C. § 621, et seq. (“ADEA”), Title VII of the Civil Rights Act of 1964, as amended, 42 U.S.C. § 2000e,
et seq., the Americans with Disabilities Act of 1990, 42 U.S.C. § 12101, et seq., the Family and Medical Leave Act, 42 U.S.C. § 2601, et seq., any common law or statutory claim of wrongful
discharge, the Employment Retirement Income Security Act of 1976, as amended, and any claims for any entitlement to severance, vacation pay, accrued paid leave, commissions, reimbursements or attorney’s fees pursuant to any contract or state or
federal law. 
 By entering into this Agreement, the Company and Zorn understand and agree that Zorn does not waive any rights
or claims that he might have that arise as a result of any conduct that occurs after the date he signs this Agreement, any rights or claims that he might have under that certain Indemnification Agreement between Zorn and the Company made and entered
into as of April 11, 2006 (the “Indemnification Agreement”) that arise as a result of any claims asserted or proceedings initiated after the date he signs this Agreement, any claims for continuation rights under COBRA, or any
rights or claims that cannot be waived by law. 
 Zorn acknowledges and agrees that: (i) any and all monies due and owing
to Zorn from Targacept, including, without limitation, any and all compensation, wages, commissions, benefits, expense reimbursements, vacation/leave time, and any other payments due and owing Zorn from Targacept, have heretofore been
unconditionally and timely paid to Zorn and that Targacept has satisfied each and every obligation owing to Zorn, except for: (A) Zorn’s regular base salary through the Resignation Date, which shall be paid by Targacept in arrears in
accordance with its customary payroll practices; (B) Zorn’s eligible, unused floating holiday and vacation days as of Resignation Date; (C) the amount set forth in Section 1 of the Retention Award Agreement between Zorn and
Targacept dated January 17, 2013 (the “Retention Award Agreement”), subject to the terms and conditions of the Retention Award Agreement, which amount shall be payable to Zorn within thirty (30) days after
September 30, 2013; (D) the amounts to be paid to Zorn by Targacept pursuant to this 

  
 Page 4 of 8

 
Agreement; and (E) any reimbursable business expenses actually and reasonably incurred prior to the Resignation Date (including, without limitation, out-of-pocket expenses, not to exceed
$2,000 in the aggregate, associated with continuing legal education for 2013), which shall, to the extent consistent with all applicable Company policies and practices and supported by adequate documentation, be paid by Targacept in accordance with
its customary practices; and (ii) there are no stock options, stock grants, equity compensation, bonus commitments or incentive compensation of any kind or nature whatsoever which are due and owing to Zorn (including, without limitation, with
respect to Targacept’s annual cash incentive award program, commonly referred to within Targacept as its bonus program, with respect to 2013 or any other year) and no such payment or entitlement will accrue or become due and owing after the
Resignation Date. 
 12. AGREEMENT TO COOPERATE. In
addition to, and not in lieu of, Zorn’s other obligations hereunder, Zorn agrees to cooperate in all reasonable respects (including, without limitation, by providing sworn testimony in affidavits, depositions, or trials) in assisting in the
prosecution or defense of any claims, demands, complaints, or lawsuits filed by or against, or threatened against, any of the Releasees that involve facts or decisions in which or about which he had, or is alleged to have had, input or knowledge for
so long as Targacept may require. Targacept will reimburse Zorn for any out-of-pocket expenses that are both approved by Targacept prior to incurrence by Zorn and actually and reasonably incurred by Zorn in the performance of this Section 12.

 13. COVENANTS.  

(a) Zorn acknowledges and affirms his obligations under Section 5 of the Employment Agreement, which survive the Resignation Date.
Zorn and the Company further hereby acknowledge and agree that the obligations of Zorn under Section 5(b) of the Employment Agreement apply mutatis mutandis to “Proprietary Information” (as that term is defined in the
Employment Agreement) learned by or made available to Zorn during the Transition Period and shall survive the end of the Transition Period. 
 (b) Zorn agrees that he will refrain from any interference with Targacept’s business opportunities and from any and all remarks or conduct that are inconsistent with the non-adversarial spirit of
this Agreement, including, without limitation, refraining from comments, oral or written, that disparage, defame, libel, slander, or otherwise damage Targacept, its business, its scientific areas of interest (e.g., neuronal nicotinic receptors) or
any of its product candidates, or any of the Releasees. 
 14. FULL
CAPACITY. Zorn attests that he possesses sufficient education and experience to understand fully the extent and impact of the provisions of this Agreement. Zorn affirms that he is fully competent to execute this
Agreement and that he does so voluntarily and without any coercion, undue influence, threat or intimidation of any kind or type. Zorn represents that he has not assigned or transferred any of the claims released under this Agreement. 

15. DISPUTED CLAIMS. It is agreed by both parties that this Agreement shall
not in any way be construed, directly or indirectly, as an admission by Targacept that it has acted wrongfully with respect to Zorn or any other person, or that Zorn has any rights whatsoever against Targacept, other than as expressly herein stated.
Targacept expressly disclaims and denies any liability to or wrongful acts against Zorn or any other person on the part of Targacept or any agents, directors, officers, attorneys, employees, or representatives of Targacept. 

  
 Page 5 of 8

 16. ADVICE TO SEEK
COUNSEL. Zorn acknowledges and agrees that he has been encouraged by Targacept to consult with counsel of his choosing prior to executing this Agreement. 

17. CONSIDERATION AND REVIEW PERIOD. Zorn agrees
that he has been provided twenty-one (21) days in which to consider and review this Agreement and to obtain any legal advice Zorn deems appropriate from the attorney of his choice. 

18. REVOCATION PERIOD. After returning a signed original of this Agreement to
the Company, Zorn may revoke his agreement in Section 11 to waive claims arising under the Age Discrimination in Employment Act of 1967 (“ADEA”) by providing written notice to Targacept within seven (7) days after the date
of signature of the later of Zorn or Targacept to sign below (the “ADEA Revocation Right”). The ADEA Revocation Right will be exercised by Zorn only if Zorn provides such written notice to Targacept, Inc., 100 North Main Street,
Suite 1510, Winston-Salem, NC 27101-4072, Attn: Stephen A. Hill, President and Chief Executive Officer. 
 19.
RETURN OF PROPERTY. Zorn covenants that: 
 (a) On or
before the Resignation Date, he shall: (i) return to Targacept all property (including, for clarity but without limitation, Proprietary Information, as that term is defined in the Employment Agreement) belonging to Targacept, including, without
limitation, all keys, badges, virtual private network (vpn) fobs, phones or other handheld devices and computers (to the extent not purchased from Targacept), equipment, software, documents, handbooks, manuals, files and other materials and
information obtained by or furnished to Zorn in connection with his employment with the Company; and (ii) provide to Karen A. Hicks, Vice President, Human Resources, all user names, passwords, access codes and the like in his possession or
control, or of which he is aware, related to Targacept or any Targacept database or other property or system; and (iii) remove from any personal computer(s) and media any and all information concerning Targacept that he obtained in connection
with his employment with the Company, including without limitation, Proprietary Information. Notwithstanding anything herein to the contrary, the Company shall reimburse Zorn for all out-of-pocket costs incurred by Zorn to ship to the Company
equipment or other materials from his office in Massachusetts, if any. 
 (b) On or before the last day of the Transition Period
he shall: (i) return to Targacept all property (including, for clarity but without limitation, Proprietary Information made available to Zorn during the Transition Period) belonging to Targacept, including, without limitation, all keys, badges,
virtual private network (vpn) fobs, phones or other handheld devices, computers, equipment, software, documents, handbooks, manuals, files and other materials and information obtained or furnished to Zorn to enable the performance of Transition
Services; and (ii) remove from any personal computer(s) and media any and all information concerning Targacept that he obtained in connection with his performance of Transition Services, including without limitation, Proprietary Information.

 20. PERFORMANCE. Targacept will make the payments and provide the benefits set
forth in Section 4(a) provided Zorn complies with and meets his obligations under this Agreement and Section 5 of the Employment Agreement. In the event that Zorn breaches any of his covenants or promises, or causes any covenants or
promises to be breached, in addition to any other rights or remedies available to Targacept, at law or otherwise, Targacept’s obligation to perform under this Agreement shall automatically terminate and Targacept shall have no further liability
or obligation to Zorn. Alternatively, Targacept may seek injunctive relief to enforce the provisions of this Agreement. 

  
 Page 6 of 8

 21. ENTIRE AGREEMENT; COMPLETE
DEFENSE. The parties acknowledge and represent that, with the express exception of (a) Section 5 of the Employment Agreement, (b) the Retention Award Agreement, (c) the Stock Option Letter
Agreement, and (d) the Indemnification Agreement, which survive the Resignation Date and remain in full force and effect, this Agreement contains the entire agreement between them regarding the matters set forth and that it supersedes all
previous negotiations, discussions, communications and understandings regarding such matters. The parties further acknowledge that no representations, inducements, promises or agreements, oral or written, have been made by either party or by anyone
acting on behalf of either party that are not embodied in this Agreement. The terms of this Agreement are contractual and not a mere recital and the parties agree that the contents of this Agreement may be used in evidence to demonstrate Zorn’s
knowing and valid release of claims as stated herein. 
 The parties agree that the General Release contained in Section 11
(subject to the third paragraph thereof) may be treated as a complete defense to any legal, equitable or administrative action that may be brought, instituted or taken by Zorn, or on his behalf, against any of the Releasees and shall forever be a
complete bar to the commencement or prosecution of any claim, demand, lawsuit, charge or other legal proceeding of any kind against any of the Releasees relating to Targacept, Targacept’s business, Zorn’s employment with Targacept and the
termination of Zorn’s employment with Targacept. 
 22. APPLICABLE LAW
AND FORUM. North Carolina law shall govern the interpretation and enforcement of this Agreement, without regard to its conflicts of laws provisions. Zorn agrees that the exclusive and convenient
forum for any civil lawsuit relating to this Agreement shall be any proper state court within Forsyth County in the State of North Carolina or, if jurisdiction exists, the United States District Court for the Middle District of North Carolina.

 23. PARTIAL INVALIDITY. The parties agree that the provisions of
this Agreement shall be deemed severable and that the invalidity or unenforceability of any portion or any provision shall not affect the validity or enforceability of the other portions or provisions. Such provisions shall be appropriately limited
and given effect to the extent that they may be enforceable. 
 24. BINDING AGREEMENT;
ASSIGNMENT. This Agreement shall be binding upon and inure to the benefit of Zorn, on the one hand, and to Targacept and its successors and permitted assigns, on the other hand. This Agreement and any rights or
obligations hereunder may be assigned by the Company to the successor of all or substantially all of its business or to an affiliate of the Company. Neither this Agreement nor any of the rights and obligations of Zorn hereunder may be assigned or
delegated by Zorn without the Company’s prior written consent. 

  
 Page 7 of 8

 25. NOTICES. Any notice or other communication
hereunder shall be given in writing to the applicable party at its address (or email address) below (or such other address as such party designates by written notice given to each other party): 

 

			
	 Peter A. Zorn

[ADDRESS]
	  	 Targacept, Inc.
 100 North Main
Street, Suite 1510
 Winston-Salem, NC 27101-4072
 Attention: Stephen A. Hill, President and
 Chief Executive Officer

stephen.hill@targacept.com

 Notices shall be deemed received upon actual delivery. 

26. AMENDMENT AND WAIVER. This Agreement may not be modified or
amended except in a writing signed by Zorn and an authorized representative of the Company. The failure of either party to assert a right hereunder or to insist upon compliance with any term or condition hereof will not constitute a waiver of that
right or excuse a similar subsequent failure to perform any such term or condition by the other party. 
 27.
NO THIRD PARTY BENEFICIARIES. This Agreement is for the sole benefit of Zorn, on the one hand, and the Company and its permitted successors and assigns, on the
other hand, and shall not be construed as conferring any rights on any other party. 
 IN WITNESS WHEREOF, the parties have set
their hands and seals on this Agreement: 
  

									
	 /s/ Peter A. Zorn
	 		 	Date:	 	 8/13/13

	Peter A. Zorn	 		 		 	
				
	TARGACEPT, INC.	 		 		 	
					
	By:	 	 /s/ Stephen A. Hill
	 		 	Date:	 	 August 13, 2013

		 	Stephen A. Hill	 		 		 	
		 	President and Chief Executive Officer	 		 		 	

  
 Page 8 of 8EX-4.02

 Exhibit 4.02 
 CHEGG, INC. 
 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 March 7, 2012 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
			
	1.	 	 Registration Rights
	  	 	2	  
	 1.1.
	 	 Definitions
	  	 	2	  
	 1.2.
	 	 Request for Registration
	  	 	3	  
	 1.3.
	 	 Company Registration
	  	 	5	  
	 1.4.
	 	 Obligations of the Company
	  	 	5	  
	 1.5.
	 	 Furnish Information
	  	 	7	  
	 1.6.
	 	 Expenses of Demand Registration
	  	 	7	  
	 1.7.
	 	 Expenses of Company Registration
	  	 	7	  
	 1.8.
	 	 Underwriting Requirements
	  	 	7	  
	 1.9.
	 	 Delay of Registration
	  	 	8	  
	 1.10.
	 	 Indemnification
	  	 	8	  
	 1.11.
	 	 Reports Under Securities Exchange Act
	  	 	11	  
	 1.12.
	 	 Form S-3 Registration
	  	 	11	  
	 1.13.
	 	 Transfer or Assignment of Registration Rights
	  	 	14	  
	 1.14.
	 	 Limitations on Subsequent Registration Rights
	  	 	14	  
	 1.15.
	 	 “Market Stand-Off” Agreement
	  	 	14	  
	 1.16.
	 	 Termination of Registration Rights
	  	 	15	  
			
	2.	 	 Covenants of the Company to the Investors
	  	 	15	  
	 2.1.
	 	 Information Rights
	  	 	15	  
	 2.2.
	 	 Visitation and Inspection
	  	 	16	  
	 2.3.
	 	 Right of First Offer
	  	 	16	  
	 2.4.
	 	 Other Covenants
	  	 	18	  
	 2.5.
	 	 Observer Rights
	  	 	19	  
	 2.6.
	 	 Confidentiality, Assignment and Termination of Covenants
	  	 	19	  
			
	3.	 	 Investment Activities
	  	 	20	  
			
	4.	 	 Legend
	  	 	21	  
			
	5.	 	 Miscellaneous
	  	 	21	  
	 5.1.
	 	 Governing Law
	  	 	21	  
	 5.2.
	 	 Waiver of Right of First Offer
	  	 	21	  
	 5.3.
	 	 Waivers and Amendments
	  	 	21	  
	 5.4.
	 	 Successors and Assigns
	  	 	22	  
	 5.5.
	 	 Entire Agreement
	  	 	22	  
	 5.6.
	 	 Notices
	  	 	22	  
	 5.7.
	 	 Interpretation
	  	 	22	  
	 5.8.
	 	 Severability
	  	 	23	  
	 5.9.
	 	 Aggregation of Stock
	  	 	23	  
	 5.10.
	 	 Counterparts
	  	 	23	  
	 5.11.
	 	 Telecopy Execution and Delivery
	  	 	23	  
	 5.12.
	 	 Delay or Omission
	  	 	23	  

  
 i 

							
	 5.13.
	 	 Specific Performance
	  	 	24	  
	 5.14.
	 	 Termination of Series E Rights Agreement
	  	 	24	  

 SCHEDULES: 
 A      -        Schedule of Investors 

  
 ii 

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of March 7, 2012, by and
among CHEGG, INC., a Delaware corporation (the “Company”), and the individuals and entities listed on SCHEDULE A hereto (each, an “Investor” and collectively, the “Investors”),
and is effective contingent and immediately upon the Closing (as defined in the Series F Agreement (as defined below)) (the “Effective Date”). 
 RECITALS 
 WHEREAS, certain Investors hold (i) shares of the
Company’s Series A Preferred Stock and/or shares of Common Stock issued upon conversion thereof (the “Series A Stock”) pursuant to the Series A Preferred Stock Purchase Agreement, dated as of August 22,
2005, as amended from time to time, (ii) shares of the Company’s Series A-1 Preferred Stock and/or shares of Common Stock issued upon conversion thereof (the “Series A-1 Stock”) pursuant to the Series A-1 Preferred Stock Purchase Agreement, dated as of September 6, 2006, as amended from time to time,
(iii) shares of the Company’s Series B Preferred Stock and/or shares of Common Stock issued upon conversion thereof (the “Series B Stock”) pursuant to the Series B Preferred Stock Purchase Agreement, dated
as of June 11, 2008, (iv) shares of the Company’s Series C-1 Preferred Stock and/or shares of Common Stock issued upon conversion thereof (the
“Series C-1 Stock”) and Series C-2 Preferred Stock and/or shares of Common Stock issued upon conversion thereof (the “Series C-2 Stock” and, together with the Series C-1 Stock, the “Series C Stock”) pursuant to the Series C Preferred Stock
Purchase, dated as of December 9, 2008, (v) shares of the Company’s Series D Preferred Stock and/or shares of Common Stock issued upon conversion thereof (the “Series D Stock”) pursuant to the Series D
Preferred Stock Purchase Agreement, dated as of November 18, 2009, and/or (vi) shares of the Company’s Series E Preferred Stock and/or shares of Common Stock issued upon conversion thereof (the “Series E
Stock”) pursuant to the Series E Preferred Stock Purchase Agreement, dated as of August 18, 2010, and possess registration rights, information rights, rights of the first refusal and other rights pursuant to that certain Amended
and Restated Investors’ Rights Agreement, dated as of August 18, 2010, by and among the Company and such Investors (the “Series E Rights Agreement”); and 

WHEREAS, the undersigned Investors who hold Series A Stock, Series A-1 Stock,
Series B Stock, Series C Stock, Series D Stock and/or Series E Stock (the “Prior Investors”) desire to terminate the Series E Rights Agreement and to accept the rights created pursuant hereto in lieu of the
rights granted to them under the Series E Rights Agreement; and 
 WHEREAS, certain Investors have agreed to
purchase from the Company, and the Company has agreed to sell to such Investors, the Company’s Series F Preferred Stock (together with the shares of Common Stock issued upon conversion thereof, the “Series F Stock”),
such purchase being on the terms and conditions contained in the Series F Preferred Stock Purchase Agreement of even date herewith by and among the Company and such Investors, as the same may be amended from time to time in accordance with its
terms (the “Series F Agreement”): 

 NOW, THEREFORE, in consideration of the mutual promises and covenants set forth
herein, the Company and Prior Investors hereby agree that the Series E Rights Agreement shall be superseded and replaced in its entirety by this Agreement, and the parties hereto further agree as follows: 

1. Registration Rights. 
 1.1. Definitions. As used in this Agreement, the following terms shall have the meanings set forth below: 
 (a) “Commission” means the United States Securities and Exchange Commission. 
 (b) “Common Stock” means the Company’s common stock, $0.001 par value per share. 
 (c) “Conversion Stock” means the shares of Common Stock issued or issuable upon conversion of the Shares. 
 (d) “Exchange Act” means the Securities Exchange Act of 1934, as amended. 
 (e) “Form S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act
subsequently adopted by the Commission that permits inclusion or incorporation of substantial information by reference to other documents filed by the Company with the Commission. 

(f) “Holder” means any person owning or having the right to acquire Registrable Securities or any assignee thereof in
accordance with Section 1.13. 
 (g) “Preferred Stock” means the Company’s preferred stock, $0.001
par value per share. 
 (h) The terms “register,” “registered” and
“registration” refer to a registration effected by preparing and filing a registration statement or similar document in compliance with the Securities Act, and the declaration or ordering of effectiveness of such registration
statement or document. 
 (i) “Registrable Securities” means (i) the Conversion Stock, (ii) any other
shares of Common Stock held by the Holders, and (iii) any of the Company’s Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right or other security that is issued as) a dividend or other distribution with
respect to, or in exchange for, or in replacement of, the shares referenced in (i) and (ii) above; provided, however, that Registrable Securities shall not include any shares of Common Stock which have previously been registered or which
have been sold to the public either pursuant to a registration statement or Rule 144, or which have been sold in a private transaction in which the transferor’s rights under this Section 1 are not assigned. 

  
 2 

 (j) “Rule 144” means Rule 144 as promulgated by the Commission
under the Securities Act, as such Rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission. 
 (k) “Rule 145” means Rule 145 as promulgated by the Commission under the Securities Act, as such Rule may be amended from time to time, or any similar successor rule that
may be promulgated by the Commission. 
 (l) “Securities Act” means the Securities Act of 1933, as amended.

 (m) “Shares” means the shares of the Series A Stock,
Series A-1 Stock, Series B Stock, Series C Stock, Series D Stock, Series E Stock and Series F Stock. 
 1.2. Request for Registration. 
 (a) Subject to the conditions of this
Section 1.2, if the Company shall receive at any time after the earlier of (i) December 9, 2013 or (ii) one hundred eighty (180) days after the effective date of the first registration statement for a public offering of
securities of the Company (other than a registration statement relating solely to employee benefit or similar plans or a registration statement relating to a Rule 145 transaction), a written request from the Holders of at least forty percent
(40%) of the Registrable Securities then outstanding that the Company effect a registration under the Securities Act with respect to at least a majority of the Registrable Securities then outstanding and having aggregate proceeds (net of
underwriting discounts and commissions) in excess $10,000,000, then the Company shall (i) give written notice of such request to all Holders within ten (10) calendar days of the date such request is given and (ii) use its best efforts
to effect as soon as practicable (and in any event within sixty (60) calendar days of the date such request is given) the registration under the Securities Act of all Registrable Securities that the Holders request to be registered within
twenty (20) calendar days of the date the Company’s notice referred to in this subsection 1.2(a) is given. 
 (b)
If the Holders initiating the registration request hereunder (the “Initiating Holders”) intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part
of their request made pursuant to subsection 1.2(a) and the Company shall include such information in the written notice referred to in subsection 1.2(a). The underwriter will be selected by the Company and shall be reasonably acceptable to a
majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the
inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in subsection
1.4(e)) enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting. Notwithstanding any other provision of this Section 1.2, if the underwriter advises the Initiating Holders in
writing that marketing factors require a limitation of the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that would otherwise be underwritten pursuant hereto, and the number of
shares of Registrable Securities that may be included in the underwriting shall be allocated among all Holders electing to include shares in 

  
 3 

 
the underwriting, including the Initiating Holders, in proportion (as nearly as practicable) to the amount of Registrable Securities requested by each such Holder to be included in such
underwriting; provided, however, that the number of shares of Registrable Securities to be included in such underwriting shall not be reduced unless all other securities (including those to be sold for the Company’s account) are first entirely
excluded from the underwriting. For purposes of the preceding parenthetical concerning apportionment, for any selling stockholder which is a Holder of Registrable Securities and which is a partnership, limited liability company or corporation, the
partners (or retired partners), members (or retired members) and stockholders of such selling stockholder, or the estates and family members of any such partners (retired partners), members (or retired members) or stockholders and any trusts for the
benefit of any of the foregoing persons shall be deemed to be a single “selling stockholder” and any pro rata reduction with respect to such “selling stockholder” shall be based upon the aggregate amount of shares carrying
registration rights owned by all entities and individuals included in such “selling stockholder” as defined in this sentence. 
 (c) Notwithstanding the foregoing, if the Company shall furnish to the Holders requesting a registration pursuant to this Section 1.2, a certificate signed by the Company’s President stating
that in the good faith judgment of the Company’s Board of Directors, such registration would be seriously detrimental to the Company and its stockholders and that it is, therefore, essential to defer taking action with respect to such
registration, the Company shall have the right to defer taking action with respect to such filing for a period of not more than ninety (90) calendar days after the date the request of the Initiating Holders is given; provided, however,
that the Company may not utilize this right or the right set forth in Section 1.12(c) more than once in any twelve (12) month period; and provided, further, that the Company shall not register any securities for the account of
itself or any other stockholder during such ninety (90) day period other than a registration relating solely to employee benefit or similar plans, or a registration relating to a Rule 145 transaction. 

(d) In addition, the Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to this
Section 1.2: 
 (i) after the Company has effected two (2) registrations pursuant to this Section 1.2 and such
registrations have been declared or ordered effective and have remained effective for at least the period of time described in Section 1.4(a); 
 (ii) during the period starting with the date thirty (30) calendar days prior to the Company’s good faith estimate of the date of filing of, and ending on a date ninety (90) calendar days
after the effective date of, any registration statement pertaining to a public offering of securities for the Company’s account; provided that the Company is actively employing its best efforts to cause such registration statement to be
effective; 
 (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately
registered on Form S-3 pursuant to a request made pursuant to Section 1.12; or 
 (iv) in any particular jurisdiction in which the Company would be required to qualify to do business or to execute a general consent to service of process in

  
 4 

 
effecting such registration, qualification or compliance unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act. 

1.3. Company Registration. If (but without any obligation to do so) the Company proposes to register any of its stock or other
securities either for its own account or the account of a stockholder or stockholders exercising their respective demand registration rights (other than (i) a registration pursuant to Sections 1.2 or 1.12, (ii) a registration relating
solely to employee benefit or similar plans, (iii) a registration relating to a Rule 145 transaction or (iv) a registration on any form which does not permit secondary sales or does not include substantially the same information as
would be required to be included in a registration statement covering the Registrable Securities), the Company shall, at such time, promptly give each Holder written notice of such registration. Upon the written request of each Holder given within
twenty (20) calendar days of the date such notice is given, the Company shall, subject to the provisions of Section 1.8, include in the registration all of the Registrable Securities that each such Holder has requested to be registered.

 1.4. Obligations of the Company. Whenever required under this Section 1 to effect the registration of any
Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
 (a) Prepare and file with the Commission
a registration statement with respect to such Registrable Securities and use its best efforts to cause such registration statement to become effective, and, upon the request of the Holders of at least a majority of the Registrable Securities
registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) calendar days or any less period of time in the event the distribution described in the registration statement has been completed;
provided, however, that (i) such 120-day period shall be extended for a period of time equal to the period the Holder refrains from selling any securities included in such registration at the
request of an underwriter of Common Stock (or other securities) of the Company and (ii) in the case of any registration statement on Form S-3 covering securities which are intended to be offered on a
continuous or delayed basis, such 120-day period shall be extended, if necessary, to keep the registration statement effective until all such Registrable Securities are sold, provided that Rule 415, or
any successor rule under the Securities Act, permits an offering on a continuous or delayed basis, and provided further that applicable rules under the Securities Act governing the obligation to file a
post-effective amendment permit, in lieu of filing a post-effective amendment which (a) includes any prospectus required by Section 10(a)(3) of the
Securities Act or (b) reflects facts or events representing a material or fundamental change in the information set forth in the registration statement, the incorporation by reference of information required to be included in (a) and
(b) above to be contained in periodic reports filed pursuant to Section 13 or 15(d) of the Exchange Act in the registration statement; 
 (b) Prepare and file with the Commission such amendments and supplements to such registration statement and the prospectus used in connection with such registration statement as may be necessary to comply
with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement; 

  
 5 

 (c) Furnish to the Holders such numbers of copies of a prospectus, including a preliminary
prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them; 

(d) Use its best efforts to register and qualify the securities covered by such registration statement under such other securities or
blue sky laws of such jurisdictions as shall be reasonably requested by the Holders; provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to
service of process in any such states or jurisdictions; 
 (e) In the event of any underwritten public offering, enter into and
perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter(s) of such offering (each Holder participating in such underwriting shall also enter into and perform its obligations under such
an agreement); 
 (f) Notify each Holder of Registrable Securities covered by such registration statement at any time when a
prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material
fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing; 

(g) Cause all such Registrable Securities registered pursuant to this Section 1 to be listed on each securities exchange or
nationally recognized quotation system on which similar securities issued by the Company are then listed; 
 (h) Provide a
transfer agent and registrar for all Registrable Securities registered pursuant to this Section 1 and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; and 

(i) Use its best efforts to cause to be furnished, if required by the underwriting agreement executed in connection with the registration
or at the request of the Holders holding a majority of the Registrable Securities proposed to be sold in the offering, on the date that such Registrable Securities are delivered to the underwriters for sale, if such securities are being sold through
underwriters, or, if such securities are not being sold through underwriters, on the date that the registration statement with respect to such securities becomes effective, (i) an opinion, dated such date, of the counsel representing the
Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable
Securities and (ii) a letter dated such date, from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in connection with an
underwritten public offering, addressed to the underwriters, if any, and if permitted by applicable accounting standards, to the Holders requesting registration of Registrable Securities. 

  
 6 

 1.5. Furnish Information. 

(a) It shall be a condition precedent to the Company’s obligations to take any action pursuant to this Section 1 with respect
to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding such Holder, the Registrable Securities held by such Holder, and the intended method of disposition of such securities as
shall be required by the Company or the managing underwriters, if any, to effect the registration of such Holder’s Registrable Securities. 
 (b) The Company shall have no obligation with respect to any registration requested pursuant to Section 1.2 or Section 1.12 if, due to the operation of subsection 1.5(a), the number of shares or
the anticipated aggregate offering price of the Registrable Securities to be included in the registration does not equal or exceed the number of shares or the anticipated aggregate offering price required to originally trigger the Company’s
obligation to initiate such registration as specified in Section 1.2(a) or Section 1.12(c)(ii), whichever is applicable. 
 1.6. Expenses of Demand Registration. All expenses (other than underwriting discounts and commissions) incurred in connection with registrations, filings or qualifications pursuant to
Section 1.2, including (without limitation) all registration, filing and qualification fees, printer’s fees, accounting fees and fees and disbursements of counsel for the Company and the reasonable fees and disbursements of one counsel for
the selling Holders shall be borne by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 1.2 if the registration request is subsequently
withdrawn at the request of the Holders of at least a majority of the Registrable Securities to be registered (in which case all participating Holders shall bear such expenses on a pro rata basis based on the number of Registrable Securities
requested to be registered by each Holder), unless the Holders of at least a majority of the Registrable Securities agree to forfeit their right to one demand registration pursuant to Section 1.2; provided further, however, that if at
the time of such withdrawal, the Holders have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable
promptness following disclosure by the Company of such material adverse change, then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one demand registration pursuant to Section 1.2. 

1.7. Expenses of Company Registration. The Company shall bear and pay all expenses incurred in connection with any registration,
filing or qualification of Registrable Securities with respect to the registrations pursuant to Section 1.3 for each Holder, including (without limitation) all registration, filing and qualification fees, printer’s fees, accounting fees
and fees and disbursements of counsel for the Company and the reasonable fees and disbursements of one counsel for the selling Holders, but excluding underwriting discounts and commissions relating to Registrable Securities which shall be borne by
the selling Holders on a pro rata basis based on the number of Registrable Securities sold by each Holder. 
 1.8.
Underwriting Requirements. In connection with any offering involving an underwriting of shares of the Company’s capital stock, the Company shall not be required under 

  
 7 

 
Section 1.3 to include any of the Holders’ Registrable Securities in such underwriting unless they accept the terms of the underwriting as agreed upon between the Company and the
underwriters selected by it (or by other persons entitled to select the underwriters), and then only in such quantity as the underwriters determine, in their sole discretion, will not jeopardize the success of the offering by the Company. All
Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in subsection 1.4(e)) enter into an underwriting agreement in customary form with the underwriter or underwriters selected for
such underwriting. If the total amount of securities, including Registrable Securities requested by stockholders to be included in such offering, exceeds the amount of securities sold other than by the Company that the underwriters determine in
their sole discretion is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters determine in their sole
discretion will not jeopardize the success of the offering (the securities so included to be apportioned pro rata among the selling stockholders according to the total amount of securities requested to be included therein by each such selling
stockholder or in such other proportions as shall mutually be agreed to by such selling stockholders), but in no event shall (i) the amount of securities of the selling Holders included in the offering be reduced unless the securities of all
other selling stockholders included in the offering are excluded entirely or (ii) the amount of securities of the selling Holders included in the offering be reduced below thirty percent (30%) of the total amount of securities included in
such offering, unless such offering is the Qualified IPO (as such term is defined in the Company’s Amended and Restated Certificate of Incorporation, as may be amended or amended or restated from time to time (the “Restated
Certificate”)), in which case such Holders may be excluded entirely if the underwriters make the determination described above and if the securities of all other selling stockholders are excluded entirely. For purposes of the preceding
parenthetical concerning apportionment, for any selling stockholder which is a Holder of Registrable Securities and which is a partnership, limited liability company or corporation, the partners (or retired partners), members (or retired members)
and stockholders of such selling stockholder, or the estates and family members of any such partners (or retired partners), members (or retired members) or stockholders and any trusts for the benefit of any of the foregoing persons shall be deemed
to be a single “selling stockholder” and any pro rata reduction with respect to such “selling stockholder” shall be based upon the aggregate amount of shares carrying registration rights owned by all entities and individuals
included in such “selling stockholder” as defined in this sentence. 
 1.9. Delay of Registration. No Holder
shall have any right to obtain or seek an injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 1. 

1.10. Indemnification. 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each Holder, each of its officers, directors, partners, members, stockholders, legal counsel, and accountants and each
person controlling such Holder within the meaning of Section 15 of the Securities Act, with respect to which registration, qualification, or compliance has been effected pursuant to this Section 1, and each underwriter, if any, and each
person who controls within the meaning of Section 15 of the Securities Act any underwriter, against all expenses, claims, losses, damages, and liabilities (or actions, proceedings, or settlements in

  
 8 

 
respect thereof) arising out of or based on: (i) any untrue statement (or alleged untrue statement) of a material fact contained or incorporated by reference in any prospectus, offering
circular, or other document (including any related registration statement, notification, or the like) incident to any such registration, qualification, or compliance, (ii) any omission (or alleged omission) to state therein a material fact
required to be stated therein or necessary to make the statements therein not misleading, or (iii) any violation (or alleged violation) by the Company of the Securities Act, any state securities laws or any rule or regulation thereunder
applicable to the Company and relating to action or inaction required of the Company in connection with any offering covered by such registration, qualification, or compliance, and the Company will reimburse, as incurred, each such Holder, each of
its officers, directors, partners, members, stockholders, legal counsel, and accountants and each person controlling such Holder, each such underwriter, and each person who controls any such underwriter, for any legal and any other expenses
reasonably incurred in connection with investigating and defending or settling any such claim, loss, damage, liability, or action; provided that the Company will not be liable in any such case to the extent that any such claim, loss, damage,
liability, or action arises out of or is based on any untrue statement or omission based upon written information furnished to the Company by such Holder, such underwriter or any person who controls such underwriter and stated to be specifically for
use therein; and provided, further that, the indemnity agreement contained in this Section 1.10(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability, or action if such settlement is effected without
the consent of the Company (which consent shall not be unreasonably withheld). 
 (b) To the extent permitted by law, each
Holder will, if Registrable Securities held by such Holder are included in the securities as to which such registration, qualification, or compliance is being effected, indemnify and hold harmless the Company, each of its directors, officers, legal
counsel, and accountants and each underwriter, if any, of the Company’s securities covered by such a registration statement, each person who controls the Company or such underwriter within the meaning of Section 15 of the Securities Act,
each other such Holder, and each of their officers, directors, partners, members, stockholders, legal counsel and accountants and each person controlling such Holder, against all claims, losses, damages and liabilities (or actions in respect
thereof) arising out of or based on: (i) any untrue statement (or alleged untrue statement) of a material fact contained or incorporated by reference in any such registration statement, prospectus, offering circular, or other document, or
(ii) any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse the Company and such Holders, directors, officers, partners,
legal counsel, and accountants, underwriters, or control persons for any legal or any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability, or action, in each case to the extent,
but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in such registration statement, prospectus, offering circular, or other document in reliance upon and in conformity with
written information furnished to the Company by such Holder and stated to be specifically for use therein; provided, however, that the obligations of such Holder hereunder shall not apply to amounts paid in settlement of any such claims,
losses, damages, or liabilities (or actions in respect thereof) if such settlement is effected without the consent of such Holder (which consent shall not be unreasonably withheld); and provided that in no event shall any indemnity under this
Section 1.10(b), when combined with amounts paid under Section 1.10(d), exceed the net proceeds from the offering received by such Holder. 

  
 9 

 (c) Each party entitled to indemnification under this Section 1.10 (the
“Indemnified Party”) shall give notice to the party required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be
sought, and shall permit the Indemnifying Party to assume the defense of such claim or any litigation resulting therefrom; provided that counsel for the Indemnifying Party, who shall conduct the defense of such claim or any litigation
resulting therefrom, shall be approved by the Indemnified Party (whose approval shall not be unreasonably withheld), and the Indemnified Party may participate in such defense at such party’s expense; provided, however, that an
Indemnified Party (together with each other Indemnified Party which may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the reasonable fees and expenses to be paid by the Indemnifying Party,
if representation of such Indemnified Party by the counsel retained by the Indemnifying Party would be inappropriate due to actual or potential differing interests between such Indemnified Party and any other party represented by such counsel in
such proceeding. The failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations under this Section 1.10, to the extent such failure is not prejudicial. No Indemnifying Party,
in the defense of any such claim or litigation, shall, except with the consent of each Indemnified Party, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant
or plaintiff to such Indemnified Party of a release from all liability in respect to such claim or litigation. Each Indemnified Party shall furnish such information regarding itself or the claim in question as an Indemnifying Party may reasonably
request in writing and as shall be reasonably required in connection with defense of such claim and litigation resulting therefrom. 
 (d) If the indemnification provided for in this Section 1.10 is held by a court of competent jurisdiction to be unavailable to an Indemnified Party with respect to any loss, liability, claim, damage,
or expense referred to herein, then the Indemnifying Party, in lieu of indemnifying such Indemnified Party hereunder, shall contribute to the amount paid or payable by such Indemnified Party as a result of such loss, liability, claim, damage, or
expense in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party on the one hand and of the Indemnified Party on the other in connection with the statements or omissions that resulted in such loss, liability,
claim, damage, or expense as well as any other relevant equitable considerations. The relative fault of the Indemnifying Party and of the Indemnified Party shall be determined by reference to, among other things, whether the untrue or alleged untrue
statement of a material fact or the omission to state a material fact relates to information supplied by the Indemnifying Party or by the Indemnified Party and the parties’ relative intent, knowledge, access to information, and opportunity to
correct or prevent such statement or omission. In no event shall any Holder be required to contribute an amount, when combined with amounts paid pursuant to Section 1.10(b), in excess of the net proceeds from the offering received by such
Holder. 
 (e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in
the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions of the underwriting agreement shall control. 

  
 10 

 (f) The obligations of the Company and Holders under this Section 1.10 shall survive
the completion of any offering of Registrable Securities in a registration statement under this Section 1, and otherwise. 

1.11. Reports Under Securities Exchange Act. With a view to making available the benefits of certain rules and regulations of the
Commission, including Rule 144, that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company agrees
to: 
 (a) make and keep public information available, as those terms are understood and defined in Rule 144, at all times
after ninety (90) days after the effective date of the first registration statement filed by the Company for the offering of its securities to the general public; 
 (b) take such action, including the voluntary registration of its Common Stock under Section 12 of the Exchange Act, as is necessary to enable the Holders to utilize
Form S-3 for the sale of their Registrable Securities, such action to be taken as soon as practicable after the end of the fiscal year in which the first registration statement filed by the Company for
the offering of its securities to the general public is declared effective; 
 (c) file with the Commission in a timely manner
all reports and other documents required of the Company under the Securities Act and the Exchange Act; and 
 (d) furnish to any
Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) a written statement by the Company that it has complied with the reporting requirements of Rule 144 (at any time after ninety (90) calendar days
after the effective date of the first registration statement filed by the Company), the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant whose
securities may be resold pursuant to Form S-3 (at any time after it so qualifies), (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so
filed by the Company, and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the Commission that permits the selling of any such securities without registration or pursuant to such
form. 
 1.12. Form S-3 Registration. 

(a) Subject to the conditions of this Section 1.12, if the Company shall receive from the Holders of at least twenty-five percent (25%) of the Registrable Securities then outstanding a written request that the Company effect a registration on Form S-3 and any related
qualification or compliance with respect to all or a part of the Registrable Securities owned by such Holder(s), then the Company shall (i) promptly give written notice of the proposed registration, and any related qualification or compliance,
to all other Holders and (ii) use its best efforts to effect, as soon as practicable, such registration and all such qualifications and compliances as may be so requested and as would permit or facilitate the sale and distribution of all or
such portion of the Registrable Securities specified in such request, together with all or such portion of the Registrable Securities of any other Holder joining in such request as are 

  
 11 

 
specified in a written request given within fifteen (15) calendar days of the date the Company’s notice referred to in clause (a) of this sentence is given. 

(b) If the Holders requesting registration pursuant to this Section 1.12 intend to distribute the Registrable Securities covered by
their request by means of an underwriting, they shall so advise the Company as part of their request made pursuant to this Section 1.12 and the Company shall include such information in the written notice referred to in clause (i) of
Section 1.12(a). The underwriter will be selected by the Company and shall be reasonably acceptable to a majority in interest of the Holders requesting registration. In such event, the right of any Holder to include such Holder’s
Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders
proposing to distribute their securities through such underwriting shall (together with the Company as provided in Section 1.4(e)) enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such
underwriting. Notwithstanding any other provision of this Section 1.12, if the underwriter advises the Holders requesting registration in writing that marketing factors require a limitation of the number of shares to be underwritten, then the
Holders requesting registration shall so advise all Holders of Registrable Securities that would otherwise be underwritten pursuant hereto, and the number of shares of Registrable Securities that may be included in the underwriting shall be
allocated among all Holders thereof, including the Holders requesting registration, in proportion (as nearly as practicable) to the amount of Registrable Securities requested by each such Holder to be included in such underwriting; provided,
however, that the number of shares of Registrable Securities to be included in such underwriting shall not be reduced unless all other securities (including those to be sold for the Company’s account) are first entirely excluded from the
underwriting. For purposes of the preceding parenthetical concerning apportionment, for any selling stockholder which is a Holder of Registrable Securities and which is a partnership, limited liability company or corporation, the partners (or
retired partners), members (or retired members) and stockholders of such selling stockholder, or the estates and family members of any such partners (retired partners), members (or retired members) or stockholders and any trusts for the benefit of
any of the foregoing persons shall be deemed to be a single “selling stockholder” and any pro rata reduction with respect to such “selling stockholder” shall be based upon the aggregate amount of shares carrying registration
rights owned by all entities and individuals included in such “selling stockholder” as defined in this sentence. 

(c) Notwithstanding the foregoing, if the Company shall furnish to the Holder(s) requesting a registration pursuant to this
Section 1.12, a certificate signed by the Company’s President stating that in the good faith judgment of the Company’s Board of Directors, such registration would be seriously detrimental to the Company and its stockholders and that
it is, therefore, essential to defer taking action with respect to such registration, the Company shall have the right to defer taking action with respect to such filing for a period of not more than ninety (90) calendar days after the date the
request of the Holder(s) requesting a registration pursuant to this Section 1.12 is given; provided, however, that the Company shall not utilize this right or the right set forth in Section 1.2(c) more than once in any
twelve (12) month period; and provided, further, that the Company shall not register any securities for the account of itself or any other stockholder during such ninety (90) day period other than a registration

  
 12 

 
relating solely to employee benefit or similar plans, or a registration relating to a Rule 145 transaction. 
 (d) In addition, the Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to this Section 1.12: 

(i) if Form S-3 is not available for such offering by the Holders; 

(ii) if the Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration,
propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public (net of underwriting discounts and commissions) of less than $1,000,000; 

(iii) if the Company has, within the twelve (12) month period preceding the date of such request, already effected three
(3) registration on Form S-3 for the Holders pursuant to this Section 1.12; 
 (iv) during the period starting with the date thirty (30) calendar days prior to the Company’s good faith estimate of the date of filing of, and ending on a date ninety (90) calendar days
after the effective date of, any registration statement pertaining to a public offering of securities for the Company’s account; provided that the Company is actively employing its best efforts to cause such registration statement to be
effective; or 
 (v) in any particular jurisdiction in which the Company would be required to qualify to do business or to
execute a general consent to service of process in effecting such registration, qualification or compliance unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act. 

(e) All expenses incurred in connection with a registration requested pursuant to this Section 1.12 (other than underwriting
discounts and commissions which shall be borne by the selling Holders on a pro rata basis), including (without limitation) all registration, filing, qualification, printer’s fees, accounting fees, fees and disbursements of counsel for the
Company and fees and disbursements of counsel for the Holders, shall be borne by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to this
Section 1.12 if the registration request is subsequently withdrawn at the request of the Holders of at least a majority of the Registrable Securities to be registered (in which case all participating Holders shall bear such expenses on a pro
rata basis), unless the Holders of at least a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to this Section 1.12; provided further, that if at the time of such withdrawal, the Holders
have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness following disclosure by the
Company of such material adverse change, then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to this Section 1.12. Registrations effected pursuant to this
Section 1.12 shall not be counted as demands for registration or registrations effected pursuant to Sections 1.2 or 1.3, respectively. Registrations 

  
 13 

 
withdrawn (unless the Holders of at least a majority of the Registrable Securities request the withdrawal of such registration, elect not to pay the expenses therefor and agree to forfeit their
rights to one registration pursuant to this Section 1.12) shall not be counted as demands for registration or registrations effected pursuant to this Section 1.12. 
 1.13. Transfer or Assignment of Registration Rights. The rights to cause the Company to register Registrable Securities pursuant to this Section 1 may be transferred or assigned, but only with
all related obligations, by a Holder to a transferee or assignee who (i) is a subsidiary, parent, partner, limited partner, retired partner, member, former member, affiliated venture capital fund or stockholder of a Holder, (ii) is a
Holder’s family member or trust for the benefit of an individual Holder, or (iii) after such transfer, holds at least 5% of the outstanding Registrable Securities; provided that (i) prior to such transfer or assignment, the
Company is furnished with written notice stating the name and address of such transferee or assignee and identifying the securities with respect to which such registration rights are being transferred or assigned, (ii) such transferee or
assignee agrees in writing to be bound by and subject to the terms and conditions of this Agreement, including without limitation the provisions of Section 1.15 and (iii) such transfer or assignment shall be effective only if immediately
following such transfer or assignment the further disposition of such securities by the transferee or assignee is restricted under the Securities Act. 
 1.14. Limitations on Subsequent Registration Rights. From and after the Effective Date, the Company shall not, without the prior written consent of (a) the Holders of at least sixty percent
(60%) of the Registrable Securities then outstanding, (b) the Holders of a majority of the Series D Stock or the Conversion Stock issued upon conversion of the Series D Stock
then-outstanding and (c) the Holders of a majority of the Series E Stock or the Conversion Stock issued upon conversion of the Series E Stock
then-outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company which would allow such holder or prospective holder (i) to include such securities in any
registration upon terms that are more favorable to such holder or prospective holder than the terms on which the Holders may include shares in such registration or (ii) to make a demand registration. 

1.15. “Market Stand-Off” Agreement. Each Holder hereby agrees that it will not,
without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the initial public offering by the Company and ending on the date specified by the Company and the managing
underwriter (such period not to exceed one hundred eighty (180) calendar days or such longer period, not to exceed thirty-four (34) calendar days after the expiration of such 180-day period, as the Company or such managing underwriter shall request in order to facilitate compliance with FINRA rules) (i) lend, offer, pledge, sell, contract to sell, sell any option or contract to
purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any securities of the Company, including (without limitation) shares of Common Stock or
any securities convertible into or exercisable or exchangeable for Common Stock (whether now owned or hereafter acquired) or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of any securities of the Company, including (without limitation) shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock (whether now owned or hereafter acquired), whether
any such transaction described in clause 

  
 14 

 
(i) or (ii) above is to be settled by delivery of securities, in cash or otherwise. The foregoing covenants shall not apply to the sale of any shares by a Holder to an underwriter
pursuant to an underwriting agreement or to shares purchased by a Holder in the open market following the completion of the initial public offering, and shall only be applicable to the Holders if all the Company’s executive officers, directors
and greater than five percent (5%) stockholders enter into similar agreements. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Holders
subject to such agreements, based on the number of shares subject to such agreements. Each Holder agrees to execute an agreement(s) reflecting (i) and (ii) above as may be requested by the managing underwriters at the time of the
initial public offering, and further agrees that the Company may impose stop transfer instructions with its transfer agent in order to enforce the covenants in (i) and (ii) above. The underwriters in connection with the Company’s
initial public offering are intended third party beneficiaries of the covenants in this Section 1.15 and shall have the right, power and authority to enforce such covenants as though they were a party hereto. 

1.16. Termination of Registration Rights. No Holder shall be entitled to exercise any right provided for in this Section 1
after the earlier of (i) six (6) years following the consummation of the sale of securities pursuant to a registration statement filed by the Company under the Securities Act in connection with the Qualified IPO or (ii) as to any
Holder, such time, on or after the closing of the Company’s first registered public offering of Common Stock, at which all Registrable Securities held by such Holder can be sold free of restrictions and without registration in compliance with
Rule 144 of the Securities Act. 
 2. Covenants of the Company to the Investors. 

2.1. Information Rights. The Company shall deliver to each Investor who holds (and continues to hold) either (i) at least 5%
of Conversion Stock or (ii) Conversion Stock having an aggregate preferential amount payable upon a Liquidation Event (as defined in the Restated Certificate) of at least $15,000,000 (each a “Major Investor”): 

(a) as soon as practicable, but in any event within one hundred twenty (120) calendar days after the end of each fiscal year of the
Company, consolidated balance sheets of the Company and its subsidiaries, if any, as of the end of such fiscal year, and consolidated statements of income and consolidated statements of cash flows of the Company and its subsidiaries, if any, for
such year, prepared in accordance with generally accepted accounting principles (“GAAP”), all in reasonable detail and audited by independent public accountants of national standing selected by the Company; 

(b) as soon as practicable, but in any event within forty-five (45) calendar days after the
end of each of the first three (3) quarters of each fiscal year of the Company, consolidated balance sheets of the Company and its subsidiaries, if any, as of the end of such quarter, and consolidated statements of income and consolidated
statements of cash flows of the Company and its subsidiaries, if any, for such quarter prepared in accordance with GAAP, all in reasonable detail; 
 (c) as soon as practicable, but in any event within thirty (30) calendar days of the end of each month, consolidated balance sheets of the Company and its subsidiaries,

  
 15 

 
if any, as of the end of such month, and consolidated statements of income and consolidated statements of cash flows of the Company and its subsidiaries, if any, for such month prepared in
accordance with GAAP, all in reasonable detail; 
 (d) as soon as practicable, but in any event within thirty (30) calendar
days of the end of each month, executive summaries of the Company’s principal activities; and 
 (e) as soon as
practicable, but in any event within forty-five (45) calendar days prior to the end of each fiscal year, a budget and business plan for the next fiscal year, prepared on a monthly basis, including balance
sheets and income statements for such months and, as soon as prepared, any other budgets or revised budgets prepared by the Company. 
 2.2. Visitation and Inspection. The Company shall permit each Major Investor, at such Major Investor’s expense, to visit and inspect the Company’s properties, to examine its books of
account and records and to discuss the Company’s affairs, finances and accounts with its officers, all at such reasonable times as may be requested by such Major Investor; provided, however, that the Company shall not be obligated
pursuant to this Section 2.2 to provide access to any information that it reasonably considers in good faith to be a trade secret or similar confidential information. The provisions of this Section 2.2 shall not be in limitation of any
rights which any Investor may have with respect to the books and records of the Company and its subsidiaries, or to inspect their properties or discuss their affairs, finances and accounts, under the laws of the State of Delaware. 

2.3. Right of First Offer. Subject to the terms and conditions specified in this Section 2.3, the Company hereby grants to
each Investor (including any other party to which the rights set forth in this Section 2.3 have been assigned or transferred in accordance with Section 2.6(b)) (each, an “Offeree”), a right of first offer to subscribe for
and purchase such Offeree’s Pro Rata Share (as hereinafter defined for the purpose of this Section 2.3), in whole or in part, of future issuances by the Company of Future Shares (as hereinafter defined). Each Offeree shall be entitled to
assign or apportion the right of first offer among its partners and affiliates (including, in the case of a venture capital fund, other venture capital funds affiliated with such fund) in such proportions as it deems appropriate. For purposes of
this Section 2.3, an Offeree’s “Pro Rata Share” of Future Shares shall be a fraction, the numerator of which is the number of shares of Common Stock held, or issuable upon conversion of the Preferred Stock held by such
Offeree immediately prior to the issuance of Future Shares and the denominator of which is the total number of shares of the Company’s Common Stock outstanding (assuming full conversion of all outstanding Preferred Stock) immediately prior to
the issuance of Future Shares. Each time the Company proposes to offer any shares of, or securities convertible into or exercisable for any shares of, any class of its capital stock (“Future Shares”), the Company shall first make an
offering of such Future Shares to each Offeree in accordance with the following provisions: 
 (a) The Company shall deliver a
notice (“Notice”) to each Offeree stating (i) the Company’s bona fide intention to offer such Future Shares, (ii) the number of such Future Shares to be offered, and (iii) the price and a summary of the terms, if
any, upon which it proposes to offer such Future Shares. 

  
 16 

 (b) Each Offeree may elect to subscribe for and purchase, at the price and on the terms
specified in the Notice, (i) up to such Offeree’s Pro Rata Share of the Future Shares and (ii) such additional number of the Future Shares as such Offeree indicates it is willing to purchase should the other Offerees subscribe for
less than their respective Pro Rata Shares (for each Offeree, the “Additional Portion”) by notifying the Company in writing within fifteen (15) calendar days from the date the Notice is given by the Company. 

(c) If the aggregate number of Future Shares subscribed for pursuant to subsection (b) above is less than the aggregate Pro Rata
Share for which all Offerees are entitled to subscribe, then each Offeree who has subscribed for an Additional Portion pursuant to subsection (b) above shall be entitled to purchase, in addition to such Offeree’s Pro Rata Share, the
Additional Portion subscribed for by such Offeree; provided, however, that if the Additional Portions subscribed for by all Offerees exceed the difference obtained by subtracting (x) the aggregate Pro Rata Share for which all Offerees
are entitled to subscribe from (y) the number of Future Shares subscribed for by all Offerees (the “Available Additional Portion”), then each Offeree who has subscribed for an Additional Portion shall be entitled to purchase
only that portion of the Available Additional Portion as such Offeree’s Pro Rata Share bears to the aggregate Pro Rata Share for all Offerees who subscribed for an Additional Portion, subject to rounding by the Company’s Board of Directors
to the extent it reasonably deems necessary and equitable. To the extent that Future Shares are not purchased by the Offerees as provided in subsection (b) above and this subsection (c), the Company may, during the ninety (90) calendar
days following the expiration of the period provided in subsection (b) above, offer the remaining unsubscribed portion of such Future Shares to any person or persons at a price not less than and upon terms no more favorable than those specified
in the Notice. If the Company does not enter into an agreement for the sale of the Future Shares within such period, or if such agreement is not consummated within thirty (30) calendar days of the execution thereof, the right provided in this
Section 2.3 shall be deemed to be revived and such Future Shares shall not be offered unless first reoffered to the Offerees in accordance herewith. 
 (d) The right of first offer in this Section 2.3 shall not be applicable to (i) the Series F Stock sold pursuant to the Series F Agreement; (ii) the Conversion Stock;
(iii) securities issued in connection with any dividend, distribution, combination or subdivision with respect to the Common Stock or the Preferred Stock; (iv) securities issued to the Company’s employees, officers, directors,
consultants, advisors or service providers for the primary purpose of soliciting or retaining their services or for charitable purposes pursuant to any plan, agreement or similar arrangement approved by the Company’s Board of Directors,
including a majority of the Preferred Directors (as such term is defined in the Restated Certificate); (v) securities issued in connection with obtaining lease financing, whether issued to a lender, lessor, guarantor or other provider of goods
and services to the Company in a transaction entered into for primarily non-equity financing purposes and approved by the Company’s Board of Directors, including a majority of the Preferred Directors;
(vi) securities issued in connection with strategic transactions involving the Company and other entities not primarily for the financing purposes, including (a) joint ventures, manufacturing, marketing or distribution arrangements or
(b) technology transfer or development arrangements; provided that such strategic transactions and the issuance of shares therein, have been approved by the Company’s Board of Directors, including a majority of the Preferred Directors;
(vii) securities issued in a firm commitment underwritten public offering pursuant to an effective registration 

  
 17 

 
statement under the Securities Act pursuant to which all outstanding shares of each series of Preferred Stock are converted to Common Stock; (viii) securities issued in connection with a
bona fide business acquisition of or by the Company (whether by merger, consolidation, sale of assets, sale or exchange of stock or otherwise), provided such acquisition is approved by the Company’s Board of Directors, including a majority of
the Preferred Directors; (ix) securities issued upon exercise or conversion of any warrants outstanding as of the Effective Date; or (xii) up to $1,000,000 of securities (in the aggregate) issued to Triple Point Capital and Pinnacle
Ventures or their affiliates pursuant to rights granted in connection with a credit facility between the Company and such lenders. 
 2.4. Other Covenants. 
 (a) Proprietary Information and Inventions
Assignment Agreement. The Company will cause each person now or hereafter employed by it or any subsidiary with access to confidential information to enter into a proprietary information and inventions assignment agreement in the form approved
by the Company’s counsel. 
 (b) Employee and Other Stock Arrangements. Each acquisition of any
shares of the Company’s capital stock or any option or right to acquire any shares of the Company’s capital stock by an employee, consultant, officer or director of the Company will be conditioned upon the execution and delivery by the
Company and such employee, consultant, officer or director of an agreement substantially in the form approved by the Board of Directors. Unless otherwise determined by the Board of Directors, any such option or right to acquire shares of the
Company’s capital stock shall vest at the rate of one-fourth ( 1/4th) of the shares granted after one year from the date of grant and one
forty-eighth
(1/48th) of the total number of shares granted
monthly thereafter. Unless otherwise determined by the Company’s Board of Directors, any stock sold shall be subject to the Company’s right to repurchase such stock at its original purchase price and such stock shall vest on the same
schedule as set forth in the preceding sentence. 
 (c) Directors and Officers Insurance. The Company will use its
commercially reasonable efforts to cause to be maintained from financially sound and reputable insurers directors and officers insurance with coverage customary for companies similarly situated to the Company, except as otherwise decided in
accordance with policies adopted by the Company’s Board of Directors. Such policy shall not be cancelable by the Company without prior approval of the Board of Directors. 
 (d) Liability Insurance. The Company will use its commercially reasonable efforts to cause to be maintained from financially sound and reputable insurers general liability insurance in amounts
customary for companies similarly situated, except as otherwise decided in accordance with policies adopted by the Company’s Board of Directors. Such policy shall name the Company as loss payee and shall not be cancelable by the Company without
prior approval of the Board of Directors. 
 (e) Special Relationships. The Company shall not, without the unanimous
approval of the Company’s Board of Directors, offer employment as a vice president, 

  
 18 

 
executive officer or other key employee of the Company to any family member of a then current employee of the Company. 
 (f) Financial Controls. The Company shall adhere to the internal financial controls established by the audit committee of the Company’s Board of Directors (the “Audit
Committee”) during the Audit Committee meeting held on November 3, 2008. The Audit Committee shall keep the Company’s Board of Directors apprised of any developments with respect to such financial controls and shall continue to
make recommendations to the Company’s Board of Directors with respect thereto. 
 2.5. Observer Rights. A
representative designated in writing by the holders of a majority of the outstanding shares of Series E Preferred Stock (the “Board Observer”) shall have the right to attend, in a nonvoting observer capacity, all meetings of
the Company’s Board of Directors at which the Series E Director (as defined in that certain Amended and Restated Voting Agreement dated as of even date herewith by and among the Company and certain of its stockholders (as such agreement
may be amended from time to time, the “Voting Agreement”) does not attend (whether in person, by teleconference or any other means permitted by the Company’s Bylaws and/or the Delaware General Corporation Law) or any part
thereof, and, in this respect, the Company shall give the Board Observer copies of all notices, minutes, consents, and other materials that it provides to its directors; provided, however, that the Board Observer shall agree to hold in confidence
and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right to withhold any information and to exclude the Board Observer from any meeting or portion thereof if
access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of
interest. 
 2.6. Confidentiality, Assignment and Termination of Covenants. 

(a) Confidentiality. Each Investor receiving information under the covenants set forth in Sections 2.1 and 2.2 hereby agrees to
hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; provided, however, that notwithstanding the foregoing, an Investor (1) may include summary financial information concerning the Company
and general statements concerning the nature and progress of the Company’s business in an Investor’s reports to its limited partners, (2) may disclose information to its directors, officers, partners, members, stockholders, employees,
agents and advisors who have a need to know such information and (3) may disclose information to the extent required by applicable law, regulation or legal process. 
 (b) Assignment. The covenants set forth in Sections 2.1, 2.2 and 2.3 may be assigned or transferred, but only with all related obligations, by an Investor to an assignee or transferee who
(i) is a subsidiary, parent, partner, limited partner, retired partner, member, former member, affiliated venture capital fund or stockholder of a Holder, (ii) is a Holder’s family member or trust for the benefit of an individual
Holder, (iii) holds or acquires at least 5% of the Conversion Stock then outstanding or (iv) is an Investor listed on SCHEDULE A hereto. 

  
 19 

 (c) Termination. The covenants set forth in Sections 2.1, 2.2, 2.3, 2.4 and 2.5 shall
terminate as to all Investors and be of no further force or effect upon the earlier to occur of (i) the closing of a Qualified IPO (as such term is defined in the Restated Certificate) or (ii) the closing of a Change of Control (as such
term is defined in the Restated Certificate). The covenants set forth in Sections 2.1 and 2.2 shall also terminate as to all Investors and be of no further force or effect upon the date upon which the Company first becomes subject to the periodic
reporting requirements of Sections 12(g) or 15(d) of the Exchange Act. 
 3. Investment Activities. The Company
acknowledges that certain of the Investors and their affiliates, members, equity holders, director representatives, partners, employees, agents and other related persons are engaged in the business of investing in private and public companies in a
wide range of industries, including the industry segment in which the Company operates (the “Company Industry Segment”). Accordingly, the Company and the Investors acknowledge and agree that a Covered Person shall: 

(a) have no duty to the Company to refrain from participating as a director, investor or otherwise with respect to any company or other
person or entity that is engaged in the Company Industry Segment or is otherwise competitive with the Company, and 
 (b) in
connection with making investment decisions, to the fullest extent permitted by law, have no obligation of confidentiality or other duty to the Company to refrain from using any information, including, but not limited to, market trend and market
data, which comes into such Covered Person’s possession, whether as a director, investor or otherwise (the “Information Waiver”), provided that the Information Waiver shall not apply, and therefore such Covered Person shall be subject
to such obligations and duties as would otherwise apply to such Covered Person under applicable law, if the information at issue (i) constitutes material non-public information concerning the Company, or
(ii) is covered by a contractual obligation of confidentiality to which the Company is subject. 
 Notwithstanding anything
in this Section 3 to the contrary, nothing herein shall be construed as a waiver of any Covered Person’s duty of loyalty or obligation of confidentiality with respect to the disclosure of confidential information of the Company.

 For the purposes of this Section 3, “Covered Persons” shall have the meaning set forth in the Restated
Certificate. 
 Notwithstanding clause (a) of this Section 3, if a Covered Person serving as a director of the Company
is or becomes a director of an entity whose business is competitive with the Company’s business, such Covered Person shall so notify the Company promptly and, upon the Company’s request, will resign as a director of the Company (it being
understood that any such resignation shall not limit an Investor’s right to designate another individual to serve on the Company’s Board of Directors, to the extent an Investor has the right to do so under the Voting Agreement).

  
 20 

 4. Legend. Each certificate representing the shares of Common Stock and/or Preferred
Stock held by the Investors shall be endorsed with the following legend (the “Legend”): 
 THE SHARES REPRESENTED BY
THIS CERTIFICATE ARE SUBJECT TO A LOCK-UP PERIOD OF UP TO 180 DAYS FOLLOWING THE EFFECTIVE DATE OF A REGISTRATION STATEMENT OF THE COMPANY FILED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AS SET FORTH IN
THAT CERTAIN AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT BETWEEN THE CORPORATION AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE CORPORATION’S PRINCIPAL OFFICE. SUCH
LOCK-UP PERIOD IS BINDING ON TRANSFEREES OF THESE SHARES. 
 The Company agrees that,
during the term of this Agreement, it will not remove, and will not permit to be removed (upon registration of transfer, reissuance or otherwise), the Legend from any such certificate and will place or cause to be placed the Legend on any new
certificate theretofore represented by a certificate carrying the Legend. 
 5. Miscellaneous. 

5.1. Governing Law. This Agreement shall be governed in all respects by the laws of the state of California as such laws are
applied to agreements between California residents entered into and to be performed entirely within California, without regard to conflict of laws rules. 
 5.2. Waiver of Right of First Offer. Each Prior Investor holding a right of first offer to purchase new securities of the Company pursuant to Section 2.3 of the Series E Rights Agreement
by its execution of this Agreement, hereby waives any rights it may have pursuant to such section to purchase shares of Series F Stock (and any related or corresponding notice requirements) beyond that number of shares such Prior Investor is
purchasing under the Series F Agreement and, further, confirms that such Prior Investor has no rights to purchase securities of the Company in the future except as set forth in Section 2.3 hereof or except as set forth in warrants to purchase
capital stock held by such Prior Investor. 
 5.3. Waivers and Amendments. This Agreement may be terminated with the
written consent of (i) the Company, (ii) the Investors holding at least sixty percent (60%) of the Registrable Securities then outstanding (the “Majority Investors”), (iii) the Investors holding a majority of the
Series D Stock or Conversion Stock issued upon conversion of the Series D Stock then held by all Investors, and (iv) the Investors holding a majority of the Series E Stock or Conversion Stock issued upon conversion of the
Series E Stock then held by all Investors. Any term of this Agreement may be amended or waived (either generally or in a particular instance and either retroactively or prospectively) with the written consent of the Company and the
Majority Investors. Notwithstanding the foregoing, (i) this Agreement may not be amended, and 

  
 21 

 
no provision hereof may be waived, in each case, in any way which would adversely affect the rights and obligations hereunder of the Investors holding Series D Stock or Conversion Stock
issued upon conversion of the Series D Stock with respect to such shares without also the written consent of the Investors holding a majority of the Series D Stock or the Conversion Stock issued upon conversion of the Series D Stock then-held by all Investors, and (ii) this Agreement may not be amended, and no provision hereof may be waived, in each case, in any way which would adversely affect the rights and obligations hereunder of the
Investors holding Series E Stock or Conversion Stock issued upon conversion of the Series E Stock with respect to such shares without also the written consent of the Investors holding a majority of the Series E Stock or the Conversion
Stock issued upon conversion of the Series E Stock then-held by all Investors. Any termination, amendment or waiver effected in accordance with this Section 5.3 shall be binding upon each holder of
Registrable Securities then outstanding, each future holder of all such Registrable Securities and the Company. In the event of a subsequent closing with an investor as provided for in Section 1.3 of the Series F Agreement, such investor
shall become a party to this Agreement as an “Investor” upon the Company’s receipt from such investor of an executed counterpart signature page to this Agreement. 

5.4. Successors and Assigns. Except as otherwise expressly provided herein, the provisions of this Agreement shall inure to the
benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto. 
 5.5.
Entire Agreement. This Agreement constitutes the full and entire understanding and agreement among the parties with regard to the subject matter hereof, and no party shall be liable or bound to any other party in any manner by any warranties,
representations or covenants except as specifically set forth herein. 
 5.6. Notices. All notices and other
communications required or permitted under this Agreement shall be in writing and shall be delivered personally by hand or by courier, sent by overnight delivery, mailed by United States first-class mail,
postage prepaid, sent by facsimile or sent by electronic mail directed (a) if to an Investor, at such Investor’s address, facsimile number or electronic mail address set forth in the Company’s records, or at such other address,
facsimile number or electronic mail address as such Investor may designate by ten (10) days’ advance written notice to the other parties hereto or (b) if to the Company, to its address, facsimile number or electronic mail address set
forth on its signature page to this Agreement and directed to the attention of the President, or at such other address, facsimile number or electronic mail address as the Company may designate by ten (10) days’ advance written notice to
the other parties hereto. All such notices and other communications shall be effective or deemed given upon personal delivery, one (1) day after sent by overnight delivery, three (3) days after the date of mailing, upon confirmation of
facsimile transfer or upon confirmation of electronic mail delivery. 
 5.7. Interpretation. The words
“include,” “includes” and “including” when used herein shall be deemed in each case to be followed by the words “without limitation.” The titles and subtitles used in this Agreement are used for convenience
only and are not considered in construing or interpreting this Agreement. 

  
 22 

 5.8. Severability. If one or more provisions of this Agreement are held to be
unenforceable under applicable law, such provision shall be excluded from this Agreement, and the balance of the Agreement shall be interpreted as if such provision were so excluded, and shall be enforceable in accordance with its terms. 

5.9. Aggregation of Stock. All shares of Registrable Securities held or acquired by a Holder and its affiliated entities shall be
aggregated together for the purpose of determining the availability of any rights under this Agreement. For purposes of the foregoing, any shares of Registrable Securities held by a Holder that (x) is a partnership, limited liability company or
corporation shall be deemed to include shares held by (i) entities affiliated with such partnership, limited liability company or corporation, (ii) any partner (or retired partner), member (or retired member) or stockholder of such
partnership, limited liability company or corporation, (iii) the spouse, siblings, lineal descendants or ancestors of any such partner (or retired partner), member (or retired member) or stockholder, (iv) the estate of any such partner (or
retired partner), member (or retired member) or stockholder and (v) any custodian or trustee for the benefit of any such partner (or retired partner), member (or retired member) or stockholder or the spouse, siblings, lineal descendants or
ancestors of any such partner (or retired partner), member (or retired member) or stockholder and (y) is an individual shall be deemed to include shares held by (i) the estate of such individual or (ii) the spouse, siblings, lineal
descendants or ancestors of such individual and any custodian or trustee for the benefit of any of the foregoing persons. 

5.10. Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be an original, but all of
which together shall constitute one instrument. 
 5.11. Telecopy Execution and Delivery. A facsimile, telecopy or other
reproduction of this Agreement may be executed by one or more parties hereto, and an executed copy of this Agreement may be delivered by one or more parties hereto by facsimile or similar electronic transmission device pursuant to which the
signature of or on behalf of such party can be seen, and such execution and delivery shall be considered valid, binding and effective for all purposes. At the request of any party hereto, all parties hereto agree to execute an original of this
Agreement as well as any facsimile, telecopy or other reproduction hereof. 
 5.12. Delay or Omission. Except as
expressly provided herein, no delay or omission to exercise any right, power or remedy accruing to any Investor, upon any breach or default of the Company under this Agreement, shall impair any such right, power or remedy of such Investor nor shall
it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or
default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any Investor of any breach or default under this Agreement, or any waiver on the part of any Investor of any provisions or
conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any Investor, shall be cumulative and not
alternative. 

  
 23 

 5.13. Specific Performance. It is agreed and understood that monetary damages would
not adequately compensate an injured party for the breach of this Agreement by any party, that this Agreement shall be specifically enforceable, and that any breach or threatened breach of this Agreement shall be the proper subject of a temporary or
permanent injunction or restraining order. Further, each party hereto waives any claim or defense that there is an adequate remedy at law for such breach or threatened breach. 
 5.14. Termination of Series E Rights Agreement. Pursuant to Section 5.3 of the Series E Rights Agreement, the Company, the Majority Investors (as defined in the Series E Rights
Agreement), the Prior Investors holding a majority of the Series D Stock or Conversion Stock issued upon conversion of the Series D Stock held by all Prior Investors and the Prior Investors holding a majority of the Series E Stock or
Conversion Stock issued upon conversion of the Series E Stock held by all Prior Investors, by their signatures to this Agreement, hereby agree to amend and restate the Series E Rights Agreement in its entirety such that the provisions of
this Agreement shall amend and replace in their entirety the provisions of the Series E Rights Agreement, and the provisions of the Series E Rights Agreement shall have no further force and effect, in each case, as of the Effective Date.

 [Remainder of Page Intentionally Left Blank; Signature Page Follows] 

  
 24 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year
first set forth above. 
  

			
	“COMPANY”
	
	CHEGG, INC.
		
	By:	 	 /s/ Andrew Brown

		 	Andrew Brown,
		 	Chief Financial Officer

  

			
	Address:
		
	Street Address:	 	 2350 Mission College Blvd,
 Ste 1400

	City, State, ZIP:  	 	Santa Clara, CA 95054
	Facsimile:	 	408-855-5972
	Email:	 	legal@chegg.com

  
 CHEGG,
INC. 
 SIGNATURE PAGE 
 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year
first set forth above. 
  

			
	“INVESTORS”
	
	KPCB HOLDINGS, INC., AS NOMINEE
		
	By:	 	 /s/ Ted Schlein

	Name:	 	Ted Schlein
	Its:	 	Senior Vice President

  
 CHEGG,
INC. 
 SIGNATURE PAGE 
 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year
first set forth above. 
  

					
	“INVESTORS”
	
	INSIGHT VENTURE PARTNERS VI, L.P.
		 	By:	 	 Insight Venture Associates VI, L.P.,
 its general partner

		 	By:	 	 Insight VI GP, LLC,
 its
general partner

		
	By:	 	 /s/ Blair M. Flicker

		 	Name:	 	Blair M. Flicker
		 	Title:	 	Attorney-in-Fact
	
	INSIGHT VENTURE PARTNERS (CO-INVESTORS), L.P.
		 	By:	 	 Insight Venture Associates VI, L.P.,
 its general partner

		 	By:	 	 Insight VI GP, LLC,
 its
general partner

		
	By:	 	 /s/ Blair M. Flicker

		 	Name:	 	Blair M. Flicker
		 	Title:	 	Attorney-in-Fact
	
	INSIGHT VENTURE PARTNERS VI (CAYMAN), L.P.
		 	By:	 	 Insight Venture Associates VI, L.P.,
 its general partner

		 	By:	 	 Insight VI GP, LLC,
 its
general partner

		
	By:	 	 /s/ Blair M. Flicker

		 	Name:	 	Blair M. Flicker
		 	Title:	 	Attorney-in-Fact

  
 CHEGG,
INC. 
 SIGNATURE PAGE 
 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year
first set forth above. 
  

			
	“INVESTORS”
	
	ACE LIMITED
		
	By:	 	 /s/ Lim Beng Jin

		
	Name:	 	 Lim Beng Jin

		
	Title:	 	 Director

  
 CHEGG,
INC. 
 SIGNATURE PAGE 
 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year
first set forth above. 
  

			
	“INVESTORS”
	
	MOOS LLC
		
	By:	 	 /s/ Oren Zeev

	Its:	 	 Oren Zeev

  
 CHEGG,
INC. 
 SIGNATURE PAGE 
 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year
first set forth above. 
  

			
	“INVESTORS”
	
	GABRIEL VENTURE PARTNERS II, L.P.
	By:	 	Gabriel Investment Partners II, L.P.,
	Its General Partner
		
	By:	 	 /s/ Frederick W. W. Bolander

		 	Frederick W.W. Bolander, General Partner
	
	GABRIEL LEGACY FUND II, L.P.
	By:	 	Gabriel Investment Partners II, L.P.,
	Its General Partner
		
	By:	 	 /s/ Frederick W. W. Bolander

		 	Frederick W.W. Bolander, General Partner

  
 CHEGG,
INC. 
 SIGNATURE PAGE 
 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year
first set forth above. 
  

			
	“INVESTORS”
	
	FOUNDATION CAPITAL VI, LP
	By:	 	Foundation Capital Management Co. VI, LLC
		
	By:	 	 /s/ Paul Holland

		 	Manager
	
	FOUNDATION CAPITAL VI PRINCIPALS FUND, LLC
		
	By:	 	Foundation Capital Management Co. VI, LLC
		
	By:	 	 /s/ Paul Holland

		 	Manager

  
 CHEGG,
INC. 
 SIGNATURE PAGE 
 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year
first set forth above. 
  

							
		 		 	“INVESTORS”
			
		 		 	 Gothic Corporation

		 		 	(Name of Investor)
			
	 /s/ David R. Shumate
	 		 	 /s/ Edward P. Hutchinson

	David R. Shumate	 		 	(Signature of Investor or authorized signatory)
	Executive Vice President	 		 		 	
	DUMAC, LLC	 		 	 Edward P. Hutchinson

	Authorized Agent	 		 	(Print name of Investor or authorized signatory)
			
		 		 	 Investment Manager, DUMAC, LLC, Authorized Agent

		 		 	(If signing as an authorized signatory, print your title)
			
		 		 	Address:
		 		 	 DUMAC

		 		 	 280 South Mangum Street, Suite 210

		 		 	 Durham, NC 27701-3675

		 		 	Telephone:	 	 919-668-9995

		 		 	Facsimile:	 	 919-668-9926

		 		 	E-mail:	 	 investments@dumac.duke.edu

 PLEASE PROVIDE ALL OF THE ABOVE-REQUESTED INFORMATION

  
 CHEGG,
INC. 
 SIGNATURE PAGE 
 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year first set forth
above. 
  

							
	 	 	 	 	“INVESTORS”
			
		 		 	 Gothic ERP LLC

		 		 	(Name of Investor)
			
	 /s/ David R. Shumate
	 	 	 	 /s/ Edward P. Hutchinson

	David R. Shumate	 		 	(Signature of Investor or authorized signatory)
	Executive Vice President	 		 		 	
	DUMAC, LLC	 		 	 Edward P. Hutchinson

	Authorized Agent	 		 	(Print name of Investor or authorized signatory)
			
	 	 	 	 	 Investment Manager, DUMAC, LLC, Authorized Agent

		 		 	(If signing as an authorized signatory, print your title)
			
		 		 	Address:
		 		 	 DUMAC

		 		 	 280 South Mangum Street, Suite 210

		 		 	 Durham, NC 27701-3675

		 		 	Telephone:	 	 919-668-9995

		 		 	Facsimile:	 	 919-668-9926

		 		 	E-mail:	 	 investments@dumac.duke.edu

 PLEASE PROVIDE ALL OF THE ABOVE-REQUESTED INFORMATION

  
 CHEGG,
INC. 
 SIGNATURE PAGE 
 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year first set forth
above. 
  

							
		 		 	“INVESTORS”
			
		 		 	 The Duke Endowment

		 		 	(Name of Investor)
			
	 /s/ David R. Shumate
	 		 	 /s/ Edward P. Hutchinson

	David R. Shumate	 		 	(Signature of Investor or authorized signatory)
	Executive Vice President	 		 		 	
	DUMAC, LLC	 		 	 Edward P. Hutchinson

	Authorized Agent	 		 	(Print name of Investor or authorized signatory)
			
		 		 	 Investment Manager, DUMAC, LLC, Authorized Agent

		 		 	(If signing as an authorized signatory, print your title)
			
		 		 	Address:
		 		 	 DUMAC

		 		 	 280 South Mangum Street, Suite 210

		 		 	 Durham, NC 27701-3675

		 		 	Telephone:	 	 919-668-9995

		 		 	Facsimile:	 	 919-668-9926

		 		 	E-mail:	 	 investments@dumac.duke.edu

 PLEASE PROVIDE ALL OF THE ABOVE-REQUESTED INFORMATION

  
 CHEGG,
INC. 
 SIGNATURE PAGE 
 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year first set forth
above. 
  

							
		 		 	“INVESTORS”
			
		 		 	 Gothic HSP Corporation

		 		 	(Name of Investor)
			
	 /s/ David R. Shumate
	 		 	 /s/ Edward P. Hutchinson

	David R. Shumate	 		 	(Signature of Investor or authorized signatory)
	Executive Vice President	 		 		 	
	DUMAC, LLC	 		 	 Edward P. Hutchinson

	Authorized Agent	 		 	(Print name of Investor or authorized signatory)
			
		 		 	 Investment Manager, DUMAC, LLC, Authorized Agent

		 		 	(If signing as an authorized signatory, print your title)
			
		 		 	Address:
		 		 	 DUMAC

		 		 	 280 South Mangum Street, Suite 210

		 		 	 Durham, NC 27701-3675

		 		 	Telephone:	 	 919-668-9995

		 		 	Facsimile:	 	 919-668-9926

		 		 	E-mail:	 	 investments@dumac.duke.edu

 PLEASE PROVIDE ALL OF THE ABOVE-REQUESTED INFORMATION

  
 CHEGG,
INC. 
 SIGNATURE PAGE 
 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year
first set forth above. 
  

			
	“INVESTORS”
	
	 The Burgess Family Trust dated July 22, 1998

	(Name of Investor)
	
	 /s/ Robert K. Burgess

	(Signature of Investor or authorized signatory)
	
	 Robert K. Burgess

	(Print name of Investor or authorized signatory)
	
	 Trustee

	(If signing as an authorized signatory, print your title)
	
	Address:
	 Dpt 3 c/o Harris myCFO, Inc.

	 P.O. Box 10195

	 Palo Alto, CA 94303

	Telephone:	 	 650-210-5128

	Facsimile:	 	 650-210-5250

	E-mail:	 	 bur001fos@mycfo.com

 PLEASE PROVIDE ALL OF THE ABOVE-REQUESTED INFORMATION

  
 CHEGG,
INC. 
 SIGNATURE PAGE 
 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year
first set forth above. 
  

			
	“INVESTORS”
	
	 Lucas Venture Group III, LP

	(Name of Investor)
	
	 /s/ Donald A. Lucas

	(Signature of Investor or authorized signatory)
	
	 Donald A. Lucas

	(Print name of Investor or authorized signatory)
	
	 Managing Member

	(If signing as an authorized signatory, print your title)
	
	Address:
	 545 Middlefield Road, Suite 220

	 Menlo Park, CA 94025

	  

	Telephone:	 	 (650) 543-3300

	Facsimile:	 	 (650) 543-3339

	E-mail:	 	 don@lucasvg.com

 PLEASE PROVIDE ALL OF THE ABOVE-REQUESTED INFORMATION

  
 CHEGG,
INC. 
 SIGNATURE PAGE 
 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year first set forth
above. 
  

			
	“INVESTORS”
	
	 Lucas Venture Group VIII, LLC

	(Name of Investor)
	
	 /s/ Donald A. Lucas

	(Signature of Investor or authorized signatory)
	
	 Donald A. Lucas

	(Print name of Investor or authorized signatory)
	
	 Managing Member

	(If signing as an authorized signatory, print your title)
		
	Address:	 	
	 545 Middlefield Road, Suite 220

	 Menlo Park, CA 94025

	  

	Telephone:	 	 (650) 543-3300

	Facsimile:	 	 (650) 543-3339

	E-mail:	 	 don@lucasvg.com

 PLEASE PROVIDE ALL OF THE ABOVE-REQUESTED INFORMATION

  
 CHEGG,
INC. 
 SIGNATURE PAGE 
 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the day, month and year
first set forth above. 
  

			
	“INVESTORS”
	
	 GSV Capital Corp.

	(Name of Investor)
	
	 /s/ Dave D. Lapping

	(Signature of Investor or authorized signatory)
	
	 Dave D. Lapping

	(Print name of Investor or authorized signatory)
	
	 COO

	(If signing as an authorized signatory, print your title)
	
	Address:
	 GSV Capital Corp.

	 2965 Woodside Road

	 Woodside, CA 94062

	Telephone:	 	 (650) 206-2165

	Facsimile:	 	 (650) 294-4783

	E-mail:	 	 dlapping@gsvam.com

 PLEASE PROVIDE ALL OF THE ABOVE-REQUESTED INFORMATION

  
 CHEGG,
INC. 
 SIGNATURE PAGE 
 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 SCHEDULE A 

SCHEDULE OF INVESTORS 

Ace Limited 
 Insight Venture Partners VI, L.P.

 Insight Venture Partners VI (Co-Investors), L.P. 

Insight Venture Partners (Cayman) VI, L.P. 

Amit Patel 
 Charles Schwab, Inc. for the
benefit of Samuel T. Spadafora IRA 
 David M. Straus 
 Donald J. Morrison 
 Donald Katz 
 Eric Di Benedetto 
 Foundation Capital VI, LP 

Foundation Capital VI Principals Fund, LLC 

Gabriel Legacy Fund II, L.P. 
 Gabriel Venture
Partners II, L.P. 
 Greg Schroeder 

Kapil K. Nanda 
 KPCB Holdings, Inc., as
nominee 
 Larry Porter 
 Maples
Investments, L.P. 
 Millennium Technology Value Partners II, L.P. 
 Millennium Technology Value Partners II-A, L.P. 
 MJMJR Ltd. 

Mohammad Osman Rashid 

  
 S-1

 MOOS LLC 
 Naren & Vimta Gupta Living Trust dtd 12/2/94 
 Philipe White and Cindie White TTEES White
Family Trust 
 Pierre Latecoere 

Robert W. Wilmot & Mary J. Wilmot, Trustees of The Wilmot Living Trust u/d/t dated April 18th 1995 

Saints Capital VI, L.P. 
 Samuel T. &
Cheryl M. Spadafora 1992 Family Trust 
 Samuel T. Spadafora 
 Shea Ventures Opportunity Fund, LP 
 Shea Ventures Opportunity Fund A-I, LLC 

Vaish Trust dated November 26, 1990 

Pinnacle Ventures II-A, L.P. 
 Pinnacle Ventures II-B, L.P. 
 Pinnacle Ventures II-C, L.P. 
 Pinnacle Ventures II-R, L.P. 

Pinnacle Ventures Debt Fund III-A, L.P. 
 Pinnacle Ventures Debt Fund III, L.P. 
 Pinnacle Ventures Equity Fund II, L.P. 

Pinnacle Ventures Equity Fund II-O, L.P. 
 Triplepoint Capital LLC 
 Gothic Corporation 

Gothic ERP LLC 
 The Duke Endowment 

Gothic HSP Corporation 

  
 S-2

 Lucas Venture Group III, LP 
 Lucas Venture Group VIII, LLC 
 Motive Science LLC 

GSV Capital Corp. 
 Burgess Family Trust dated
July 22, 1998 

  
 S-3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}]]